Discovery of a tricyclic farnesoid X receptor agonist HEC96719, a clinical candidate for treatment of non-alcoholic steatohepatitis

Shengtian Cao,Xinye Yang,Zheng Zhang,Junwen Wu,Bo Chi,Hong Chen,Jianghong Yu,Shanshan Feng,Yulin Xu,Jing Li,Yingjun Zhang,Xiaojun Wang,Yan Wang
DOI: https://doi.org/10.1016/j.ejmech.2021.114089
IF: 7.088
2022-02-01
European Journal of Medicinal Chemistry
Abstract:Non-alcoholic fatty liver disease (NAFLD) is becoming the most predominant burden of chronic liver disease worldwide. Non-alcoholic steatohepatitis (NASH), the progressive form of NAFLD, can develop into cirrhosis and hepatocellular cancer. Unfortunately, current options for therapeutic treatment of NASH are very limited. Among multiple pathways in NASH, farnesoid X receptor (FXR), a nuclear bile acid receptor, is well-recognized as an important effective target. Here we report the synthesis and characterization of compound HEC96719 a novel tricyclic FXR agonist based on a prior high-affinity nonsteroidal molecule GW4064. HEC96719 exhibits excellent potency superior to GW4064 and obeticholic acid in in vitro and in vivo assays of FXR activation. It also shows higher FXR selectivity and more favorable tissue distribution dominantly in liver and intestine. Preclinical data on pharmacokinetic properties, efficacy, and safety profiles overall indicate that HEC96719 is a promising drug candidate for NASH treatment.
chemistry, medicinal
What problem does this paper attempt to address?